Sage Therapeutics
215 First Street
Cambridge
MA
02142
United States
Tel: 617-299-8380
Website: https://www.sagerx.com/
About Sage Therapeutics
Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner.
Stock Symbol:
SAGE
387 articles about Sage Therapeutics
-
Sage Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
2/28/2022
Sage Therapeutics, Inc. announced that the Company will participate in a fireside chat at the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 10:30am ET.
-
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
2/24/2022
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company fearlessly leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2021.
-
Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints
2/16/2022
Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced the CORAL Study in people with major depressive disorder (MDD) met the trial objectives.
-
Sage and Biogen announced positive topline results from the Phase III study of zuranolone that showed a rapid reduction in depressive symptoms after three days.
-
Sage Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
2/10/2022
Sage Therapeutics, Inc. today announced it will host a live webcast on Thursday, February 24, 2022 at 8:00 a.m. ET to announce fourth quarter and full year 2021 financial results and discuss recent business updates.
-
Another drug Vounatsos heralded was zuranolone, which Biogen is developing with Sage Therapeutics for multiple forms of depression.
-
Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022
1/4/2022
Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022.
-
Sage Therapeutics’ Third Annual FutureCast Showcases Data from All Three Brain Health Franchises
12/14/2021
In the open-label LUMINARY Study, SAGE-718 improved performance from baseline on multiple tests of cognitive function in patients with Alzheimer’s disease mild cognitive impairment and mild dementia, consistent with positive signals seen in Parkinson’s disease and Huntington’s disease.
-
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
12/8/2021
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE clinical program evaluating the efficacy and safety of zuranolone for the treatment of major depressive disorder (MDD) presented at the American College of Neuropsychopharmacology (ACNP) Congress taking place December 5-8 in San Juan, Puerto Rico.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
12/1/2021
In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two treatment courses in total.
-
The 12-month data showed that 50 mg of zuranolone was well-tolerated among adults with MDD.
-
Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
11/24/2021
Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.
-
Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
11/11/2021
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference.
-
Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
11/2/2021
Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the third quarter ended September 30, 2021.
-
Biogen’s Aduhelm (aducanumab) reported only $300,000 in third-quarter sales compared to original analyst average estimates of $10.79 million.
-
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
10/19/2021
Sage Therapeutics, Inc. and Biogen Inc. announced their plan to submit a New Drug Application to the U.S. Food and Drug Administration for zuranolone, an investigational two-week, once-daily therapeutic in the second half of 2022.
-
Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress
10/4/2021
Sage Therapeutics, Inc. and Biogen Inc. announced new data from the LANDSCAPE and NEST clinical development programs evaluating the efficacy and safety of zuranolone for the treatment of major depressive disorder and postpartum depression presented at the 34th European College of Neuropsychopharmacology Congress, taking place October 2-5, 2021.
-
Sage Therapeutics and Biogen announced positive results from their ongoing clinical trials on the efficacy and safety of zuranolone in treating major depressive disorder and postpartum depression.